News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,090 Results
Type
Article (2573)
Company Profile (45)
Press Release (37471)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (14191)
Career Advice (78)
Deals (2107)
Drug Delivery (9)
Drug Development (4143)
Employer Resources (10)
FDA (443)
Job Trends (782)
News (20270)
Policy (1057)
Tag
Academia (144)
Allergies (7)
Alliances (3492)
ALS (6)
Alzheimer's disease (59)
Antibody-drug conjugate (ADC) (27)
Approvals (446)
Artificial intelligence (31)
Autoimmune disease (8)
Automation (2)
Bankruptcy (12)
Best Places to Work (476)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (29)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (44)
Cancer (324)
Cardiovascular disease (10)
Career advice (66)
Career pathing (1)
CAR-T (31)
CDC (1)
Cell therapy (81)
Cervical cancer (2)
Clinical research (3437)
Collaboration (199)
Company closure (2)
Compensation (104)
COVID-19 (185)
CRISPR (11)
C-suite (112)
Cystic fibrosis (7)
Data (418)
Denatured (6)
Depression (11)
Diabetes (17)
Diagnostics (488)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (36)
Drug pricing (10)
Duchenne muscular dystrophy (40)
Earnings (4500)
Editorial (5)
Employer branding (1)
Employer resources (8)
Events (6400)
Executive appointments (134)
FDA (588)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (167)
Gene editing (32)
Generative AI (1)
Gene therapy (55)
GLP-1 (63)
Government (158)
Guidances (24)
Healthcare (708)
HIV (1)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Immuno-oncology (14)
Indications (4)
Infectious disease (197)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (25)
Interviews (7)
IPO (1002)
IRA (7)
Job creations (293)
Job search strategy (62)
JPM (4)
Kidney cancer (6)
Labor market (11)
Layoffs (51)
Leadership (3)
Legal (215)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (4)
Manufacturing (52)
MASH (14)
Medical device (314)
Medtech (315)
Mergers & acquisitions (1220)
Metabolic disorders (72)
Multiple sclerosis (22)
Neurodegenerative disease (27)
Neuropsychiatric disorders (10)
Neuroscience (164)
NextGen: Class of 2026 (353)
Non-profit (155)
Now hiring (11)
Obesity (32)
Opinion (17)
Ovarian cancer (17)
Pain (24)
Pancreatic cancer (21)
Parkinson's disease (11)
Partnered (4)
Patents (53)
Patient recruitment (25)
Peanut (1)
People (5875)
Pharmaceutical (5)
Phase 1 (1474)
Phase 2 (1702)
Phase 3 (915)
Pipeline (390)
Policy (16)
Postmarket research (30)
Preclinical (640)
Press Release (2)
Prostate cancer (7)
Psychedelics (3)
Radiopharmaceuticals (14)
Rare diseases (62)
Real estate (425)
Recruiting (5)
Regulatory (916)
Reports (7)
Research institute (149)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (5)
RSV (1)
Schizophrenia (16)
Series A (46)
Series B (20)
Service/supplier (2)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (497)
Stomach cancer (2)
Supply chain (4)
Tariffs (2)
The Weekly (3)
Vaccines (52)
Venture capital (15)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Last 7 days (39)
Last 30 days (145)
Last 365 days (2411)
2026 (211)
2025 (2438)
2024 (2610)
2023 (2858)
2022 (3750)
2021 (4048)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1796)
2016 (1625)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (44)
Alabama (3)
Arizona (18)
Asia (1947)
Australia (307)
California (1601)
Canada (241)
China (80)
Colorado (54)
Connecticut (16)
Delaware (5)
Europe (4016)
Florida (64)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (21)
India (2)
Indiana (60)
Japan (17)
Kansas (14)
Kentucky (1)
Maryland (48)
Massachusetts (568)
Michigan (14)
Minnesota (22)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (133)
New York (80)
North Carolina (131)
Northern California (781)
Ohio (44)
Oklahoma (2)
Oregon (6)
Pennsylvania (109)
Puerto Rico (1)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (652)
Tennessee (4)
Texas (152)
United States (3202)
Utah (5)
Virginia (11)
Washington D.C. (3)
Washington State (95)
West Virginia (1)
Wisconsin (13)
40,090 Results for "legochem biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing
Samsung Biologics today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.
February 7, 2024
·
3 min read
LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate.
December 25, 2023
·
2 min read
Business
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial
BostonGene and LegoChem Biosciences, Inc. announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers.
November 7, 2023
·
4 min read
CORRECTING and REPLACING LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate (ADC).
December 26, 2023
·
2 min read
LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development
LegoChem Biosciences Inc. and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies, building on a previously announced 2022 collaboration and license agreement.
October 16, 2023
·
3 min read
Business
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.
November 15, 2022
·
3 min read
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that is has exercised its firstof five exclusive, target-specific optionswith LegoChem Biosciences (LCB, KOSDAQ: 141080)for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications.
November 29, 2022
·
3 min read
Press Releases
Change in Number of Shares and Votes in Alligator Bioscience AB
February 1, 2026
·
1 min read
LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate
LegoChem Biosciences Inc. and Glycotope GmbH have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational tumor targeting antibodies.
July 12, 2022
·
3 min read
Press Releases
Imbed Biosciences Secures Strategic Investment from BioLab Holdings
February 4, 2026
·
2 min read
1 of 4,009
Next
